Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03812263
Recruitment Status : Recruiting
First Posted : January 23, 2019
Last Update Posted : October 19, 2020
Sponsor:
Information provided by (Responsible Party):
Rocket Pharmaceuticals Inc.

Tracking Information
First Submitted Date  ICMJE January 18, 2019
First Posted Date  ICMJE January 23, 2019
Last Update Posted Date October 19, 2020
Actual Study Start Date  ICMJE August 30, 2019
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 18, 2019)
  • Phase I: Number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 [ Time Frame: 2 years ]
    Evaluation of safety associated with treatment with RP-L201
  • Phase II: Survival following infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of survival as determined by the proportion of subjects alive at age 2 (24 months) and at least 1-year post infusion without allogeneic hematopoietic stem cell transplant
  • Phase II: Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0 [ Time Frame: 2 years ]
    Evaluation of safety associated with treatment with RP-L201
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 22, 2019)
  • CD18 expression after infusion of RP-L201 [ Time Frame: 2 years ]
    Determination of the percentage of subjects in whom infusion of RP-L201 results in a change in the percentage of neutrophils expressing CD18 to at least 10%
  • Genetic correction after infusion of RP-L201 [ Time Frame: 2 years ]
    Determination of the percentage of subjects in whom infusion of RP-L201 results in at least 10% of peripheral blood neutrophils carrying the therapeutic Chim-CD18-WPRE lentiviral vector provirus at 6 months post-infusion
  • Incidence of infections after infusion of RP-L201 [ Time Frame: 2 years ]
    Determination of the incidence and severity of bacterial or other infections (subsequent to hematopoietic reconstitution)
  • Assessment of LAD-I-associated neutrophilia after infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of change to partially normal or to normal levels of LAD-I-associated neutrophilia
  • Assessment of skin rash or periodontal abnormalities after infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of resolution (partial or complete) of any underlying skin rash or periodontal abnormalities
  • Assessment of overall survival after infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of overall survival (beyond age 24 months and beyond the initial year subsequent to investigational therapy)
Original Secondary Outcome Measures  ICMJE
 (submitted: January 18, 2019)
  • CD18 expression after infusion of RP-L201 [ Time Frame: 2 years ]
    Determination of the percentage of subjects in whom infusion of RP-L201 results in increase in the percentage of neutrophils expressing CD18 to at least 10%
  • Genetic correction after infusion of RP-L201 [ Time Frame: 2 years ]
    Determination of the percentage of subjects in whom infusion of RP-L201 results in at least 10% of peripheral blood neutrophils carrying the therapeutic Chim-CD18-WPRE lentiviral vector provirus at 6 months post-infusion
  • Incidence of infections after infusion of RP-L201 [ Time Frame: 2 years ]
    Determination of the incidence and severity of bacterial or other infections (subsequent to hematopoietic reconstitution)
  • Assessment of LAD-I-associated neutrophilia after infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of decreases (partial or to normal levels) of LAD-I-associated neutrophilia
  • Assessment of skin rash or periodontal abnormalities after infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of resolution (partial or complete) of any underlying skin rash or periodontal abnormalities
  • Assessment of overall survival after infusion of RP-L201 [ Time Frame: 2 years ]
    Evaluation of overall survival (beyond age 24 months and beyond the initial year subsequent to investigational therapy)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
Official Title  ICMJE Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene
Brief Summary The primary purpose of the Phase I portion of the study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy consisting of autologous CD34+ enriched cells transduced with the therapeutic lentiviral vector, Chim-CD18-WPRE, RP-L201. The primary objectives of the Phase II portion of the study are evaluation of survival, as determined by the proportion of subjects alive at age 2 (24 months) and at least 1-year post-infusion without allogeneic hematopoietic stem cell transplant (HSCT) and characterization of the safety and toxicity associated with the infusion.
Detailed Description

This is a pediatric non-randomized open-label Phase I/II clinical trial. The Phase I portion will include a safety evaluation and preliminary assessment of the efficacy of hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the ITGB2 gene in subjects with severe LAD-I. CD34+ cells will be transduced ex vivo with the therapeutic vector followed by cryopreservation. If the number of CD34+ cells that are available for infusion is at least 2x10e6 total CD34+ cells/kg, subjects will undergo myeloablative conditioning with intravenous busulfan. Subjects will then receive infusion of gene-corrected hematopoietic cells approximately 24 hours following the final busulfan dose.

The active agent is a self-inactivating lentiviral vector carrying the therapeutic ITGB2 gene, encoding for the human CD18 receptor (β2 integrin subunit). The therapeutic product is the subject's autologous hematopoietic stem cells that have been transduced with the lentiviral vector.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Leukocyte Adhesion Defect - Type I
Intervention  ICMJE Biological: RP-L201
CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
Study Arms  ICMJE Experimental: RP-L201
RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single intravenous infusion
Intervention: Biological: RP-L201
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 18, 2019)
9
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 2023
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • A confirmed diagnosis of severe LAD-I as demonstrated by flow cytometry indicating CD18 expression on <2% neutrophils (polymorphonuclear neutrophils (PMNs)). Subjects in which CD18+ PMNs are >2% will be considered eligible with <2% CD11a or CD11b expressing PMNs and if there is a documented ITGB2 mutation and clinical history consistent with LAD-I (or known family history).
  • At least one (1) prior significant bacterial or fungal infection US NCI CTCAE, v5.0, Grade ≥2). This criterion is not required for subjects with documented family history who meet the above inclusion criteria.
  • Age ≥3 months.
  • Considered to be an appropriate candidate for autologous transplantation of hematopoietic stem cells.
  • A competent custodial parent with legal capacity to execute an institutional review board (IRB)/ethics committee (EC)-approved consent form must be available to participate in the consent process. (Informed assent will be sought from capable subjects, in accordance with the directive of the IRB/EC and with local requirements).
  • Ability to comply with trial procedures including investigational therapy and follow-up evaluations.

Exclusion Criteria:

  • Availability of a medically-eligible human leukocyte antigen (HLA)-identical sibling donor transplant. Subjects may not be included in this trial as an alternative to a clinically-indicated and feasible HLA-matched sibling donor hematopoietic stem cell transplant. If an HLA-identical sibling is identified, but mobilized peripheral blood or bone marrow hematopoietic stem cell collection is not feasible (for example: donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo donation procedure because of medical impairments), then inclusion may be permitted per Investigator discretion.
  • Hepatic dysfunction as defined by either:

    • Bilirubin >1.5× the upper limit of normal (ULN) or
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5×ULN.
  • Renal dysfunction as defined by either Grade 3 or higher abnormalities in serum sodium, potassium, calcium, magnesium or phosphate as defined by NCI CTCAE v5.0, or the requirement for either peritoneal dialysis or hemodialysis.
  • Pulmonary dysfunction as defined by either:

    • Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection).
    • Oxygen saturation (by pulse oximetry) <90%.
  • Evidence of active metastatic or locoregionally advanced malignancy (including hematologic malignancy) for which survival is anticipated to be less than 3 years.
  • Serious infections with persistent bloodstream pathogens at time of trial entry. (Subjects with active infections (e.g., unresolved ulcerative lesions, skin or oral infections) are permitted as long as appropriate antibiotic therapy has been (or is being) administered).
  • Any medical or other contraindication for both leukapheresis and bone marrow harvest procedure, as determined by the treating Investigator.
  • Any medical or other contraindication for the administration of conditioning therapy, as determined by the treating Investigator.
  • Significant medical conditions, including documented human immunodeficiency virus (HIV) infection, poorly-controlled diabetes, poorly-controlled hypertension, poorly-controlled cardiac arrhythmia or congestive heart failure; or arterial thromboembolic events (including stroke or myocardial infarction) within the 6 prior months.
  • Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 3 Months and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: LAD Clinical Trial 646-627-0033 ladclinicaltrial@rocketpharma.com
Contact: LAD Clinical Trial ladclinicaltrial@rocketpharma.com
Listed Location Countries  ICMJE United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03812263
Other Study ID Numbers  ICMJE RP-L201-0318
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Rocket Pharmaceuticals Inc.
Study Sponsor  ICMJE Rocket Pharmaceuticals Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Donald B Kohn, MD University of California, Los Angeles
Principal Investigator: Claire Booth University College London Great Ormond Street Institute of Child Helath
PRS Account Rocket Pharmaceuticals Inc.
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP